Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,822 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,088 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02414516 | A Dose-Escalation Study of OBP-801 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 17 | Oncolys BioPharma IncINDUSTRY | 1 | Mar 13, 2019 | clinicaltrials |
| NCT03844438 | A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors | unknown | Phase 1 | 30 | Luye Pharma Group Ltd.INDUSTRY | 1 | Feb 20, 2019 | clinicaltrials |
| NCT03815084 |
| A Study of PD1 Combined With DC-NK Cell in the Treatment of Solid Tumors |
| unknown |
| Early Phase 1 |
| 100 |
| Allife Medical Science and Technology Co., Ltd.INDUSTRY |
| 0 |
| Jan 30, 2019 |
| clinicaltrials |
| NCT03815630 | A Study of PD1 Combined With Dc-cik in the Treatment of Solid Tumors(DC-CIK) | unknown | Early Phase 1 | 100 | Allife Medical Science and Technology Co., Ltd.INDUSTRY | 0 | Jan 30, 2019 | clinicaltrials |
| NCT03618043 | Safety and Tolerability of SH-1028 in Patients With Advanced Solid Cancer | unknown | Phase 1 | 14 | Nanjing Sanhome Pharmaceutical, Co., Ltd.INDUSTRY | 1 | Jan 29, 2019 | clinicaltrials |
| NCT02968485 | Phase I Study of SHR7390 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 60 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 15, 2019 | clinicaltrials |
| NCT00020605 | Naloxone in Treating Constipation in Patients Who Are Receiving Opioids for Chronic Pain | unknown | Phase 3 | — | Dana-Farber Cancer InstituteOTHER | 1 | Dec 13, 2018 | clinicaltrials |
| NCT03638804 | 89Zr-KN035 PET Imaging in Patients With Advanced Solid Tumors | unknown | N/A | 10 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 5, 2018 | clinicaltrials |
| NCT03747965 | Study of PD-1 Gene-knocked Out Mesothelin-directed CAR-T Cells With the Conditioning of PC in Mesothelin Positive Multiple Solid Tumors | unknown | Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT03731390 | GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma | unknown | Phase 1 | 30 | Chinese Academy of Medical SciencesOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT02366546 | Investigator Initiated Phase 1 Study of TBI-1301 | unknown | Phase 1 | 9 | Mie UniversityOTHER | 1 | Oct 24, 2018 | clinicaltrials |
| NCT03692520 | Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCT200 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 90 | Sinocelltech Ltd.INDUSTRY | 1 | Oct 2, 2018 | clinicaltrials |
| NCT03628131 | Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors | unknown | Phase 1 / Phase 2 | 46 | Samsung Medical CenterOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT02787876 | Pegteograstim in Children With Solid Tumors | unknown | Phase 2 | 34 | Samsung Medical CenterOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT03615313 | PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor(PAEMCMPAST) | unknown | Phase 1 / Phase 2 | 50 | Shanghai Cell Therapy Research InstituteOTHER | 1 | Aug 3, 2018 | clinicaltrials |
| NCT03415100 | Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours | unknown | Phase 1 | 30 | The Third Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 1, 2018 | clinicaltrials |
| NCT03596593 | Identifying MSI Status From ctDNA in Chinese Patients With Refractory Advanced Solid Tumors(IMPACT) | unknown | N/A | 8,000 | Peking UniversityOTHER | 1 | Jul 24, 2018 | clinicaltrials |
| NCT03529526 | Study of the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Antitumor Activity of KN046 in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 21 | Alphamab (Australia) Co Pty Ltd.INDUSTRY | 1 | May 22, 2018 | clinicaltrials |
| NCT02884479 | An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study | unknown | Phase 1 / Phase 2 | 75 | SciClone Pharmaceuticals International (Cayman) Development LimitedINDUSTRY | 1 | Apr 25, 2018 | clinicaltrials |
| NCT03503604 | A Study of Anti-VEGF Monoclonal Antibody hPV19 in Patients With Solid Tumors | unknown | Phase 1 | 18 | SuZhou Stainwei Biotech Inc.INDUSTRY | 1 | Apr 20, 2018 | clinicaltrials |
| NCT03472352 | Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Solid Tumors | unknown | Phase 1 | 15 | Hangzhou Converd Co., Ltd.INDUSTRY | 0 | Mar 21, 2018 | clinicaltrials |
| NCT03439761 | An Open-label Phase I/II Clinical Trial of PT-112 Injection for Advanced Solid Tumors and Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 125 | SciClone PharmaceuticalsINDUSTRY | 1 | Mar 16, 2018 | clinicaltrials |
| NCT03076372 | A Study Evaluating MM-310 in Patients With Solid Tumors | unknown | Phase 1 | 34 | Merrimack PharmaceuticalsINDUSTRY | 1 | Feb 27, 2018 | clinicaltrials |
| NCT03311100 | Immunological Profile of Solid Tumors Sample | unknown | — | 1,040 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Jan 30, 2018 | clinicaltrials |
| NCT03398720 | Safety and Tolerability of HTI-1066 in Subjects With Advanced Solid Tumors | unknown | Phase 1 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Jan 12, 2018 | clinicaltrials |
| NCT03389815 | A Study Evaluates the Safety, Pharmacokinetics and Efficacy of WX-0593 in Advanced Solid Tumor Patients | unknown | Phase 1 / Phase 2 | 48 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jan 4, 2018 | clinicaltrials |
| NCT03313219 | Pharmacokinetics and Tolerancebility Studies of Gentuximab Injection in the Treatment ofPatients With Late Recurrence of Metastatic Solid Tumors in China | unknown | Phase 1 | 20 | Changchun GeneScience Pharmaceutical Co., Ltd.INDUSTRY | 1 | Dec 12, 2017 | clinicaltrials |
| NCT02940132 | A Study of SC10914 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 72 | Jiangxi Qingfeng Pharmaceutical Co. Ltd.INDUSTRY | 1 | Dec 6, 2017 | clinicaltrials |
| NCT03326479 | POA Retrospective Repository | unknown | — | 10,000 | Caris Science, Inc.INDUSTRY | 1 | Oct 31, 2017 | clinicaltrials |
| NCT02093325 | A Study to Assess the Efficacy and Safety of Eltrombopag as a Rescue of Isolated Chemotherapy-induced Thrombocytopenia | unknown | Phase 3 | 83 | Chang Gung Memorial HospitalOTHER | 1 | Oct 24, 2017 | clinicaltrials |
| NCT03260179 | Study to Evaluate the Safety, Preliminary Efficacy and Pharmacokinetics of 3810 | unknown | Phase 1 | 60 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Aug 24, 2017 | clinicaltrials |
| NCT02870036 | Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors | unknown | Phase 1 | 243 | Haihe Biopharma Co., Ltd.INDUSTRY | 1 | Jul 14, 2017 | clinicaltrials |
| NCT03182803 | CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 40 | Shanghai Cell Therapy Research InstituteOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT03182816 | CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 40 | Shanghai Cell Therapy Research InstituteOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT03179007 | CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 40 | Shanghai Cell Therapy Research InstituteOTHER | 1 | Jun 7, 2017 | clinicaltrials |
| NCT03171220 | Neoantigen Reactive T Cells Combined With SHR-1210 for Chinese Patients With Advanced Refractory Solid Tumors(NRT-01) | unknown | Phase 1 / Phase 2 | 40 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT03047811 | The Study of Targeted NY-ESO-1 T Cell Receptor (TCR) Genetic Modified Autologous T Cells Treatment of Advanced Solid Tumors | unknown | N/A | 15 | Fudan UniversityOTHER | 1 | Feb 9, 2017 | clinicaltrials |
| NCT03030001 | PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies | unknown | Phase 1 / Phase 2 | 40 | Ningbo Cancer HospitalINDUSTRY | 1 | Jan 24, 2017 | clinicaltrials |
| NCT02999750 | EXtendedAnalysis for Cancer Treatment | unknown | N/A | 55 | Medical University of ViennaOTHER | 1 | Dec 21, 2016 | clinicaltrials |
| NCT02977364 | A Trial of C-met Kinase Inhibitor HS-10241 in Subjects With Advanced Solid Tumours | unknown | Phase 1 | 50 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 30, 2016 | clinicaltrials |
| NCT02862028 | PD-1 Antibody Expressing CAR-T Cells for EGFR Family Member Positive Advanced Solid Tumor (Lung, Liver and Stomach) | unknown | Phase 1 / Phase 2 | 20 | Shanghai International Medical CenterINDUSTRY | 1 | Aug 25, 2016 | clinicaltrials |
| NCT02844881 | Study of Apatinib and MASCT in Patients With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 60 | The First People's Hospital of LianyungangOTHER | 1 | Aug 11, 2016 | clinicaltrials |
| NCT02858232 | MASCT-I Treatment for Advanced Solid Tumor | unknown | Phase 1 / Phase 2 | 46 | The First People's Hospital of LianyungangOTHER | 0 | Aug 11, 2016 | clinicaltrials |
| NCT01803503 | Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors | unknown | Phase 2 | 80 | National University Hospital, SingaporeOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT02020226 | A Cardiac Safety Study of TH-302 in Patients With Advanced Solid Tumors | unknown | Phase 1 | 40 | Threshold PharmaceuticalsINDUSTRY | 1 | Jun 2, 2016 | clinicaltrials |
| NCT01929486 | Phase Ia/Ib Multicenter Trial of Mogamulizumab for Advanced or Recurrent Cancer. | unknown | Phase 1 | 58 | Aichi Medical UniversityOTHER | 1 | Feb 17, 2016 | clinicaltrials |
| NCT01799083 | Lower Dose Decitabine Based Therapy in Patients With Refractory and/or Chemotherapy Resistant Solid Tumors or B Cell Lymphomas(CIK) | unknown | Phase 1 / Phase 2 | 100 | Han weidongOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01694472 | Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors | unknown | Phase 1 | 15 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Dec 22, 2015 | clinicaltrials |
| NCT02263950 | A Phase 1/2a Study of LON002 in Subjects With Advanced Solid Tumours(LON002-002) | unknown | Phase 1 / Phase 2 | 87 | LondonPharma Ltd.INDUSTRY | 1 | Sep 7, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Mar 13, 2019source: clinicaltrials